PCI Biotech to present at the 9th International mRNA Health Conference
09 Noviembre 2021 - 2:30AM
PCI Biotech to present at the 9th International mRNA Health
Conference
Oslo (Norway), 9 November 2021 – PCI Biotech
(OSE: PCIB), a clinical-stage biopharma company developing
innovative therapeutics that address significant unmet medical
needs in cancer today announced that it will present a poster at
the 9th International mRNA Health Conference, a combined on-site
and virtual event taking place November 9-10, 2021 in Berlin,
Germany.
Today at 16:45 – 18:30 (CET), Dr. Anders Høgset,
CSO, will on-site present a poster named ‘Photochemical
internalisation (PCI) - enhanced and site-directed mRNA delivery by
light-induced endosomal release’ giving an overview of PCI
Biotech’s proprietary platform technology for use in the exciting
field of mRNA-based therapies. Please find the poster enclosed.
Contact
information: Per
Walday,
CEO pw@pcibiotech.noMobile:
+47 917 93 429
About The International
mRNA Health
Conference The
International mRNA Health Conference is the premier meeting
destination for industry and academic professionals to explore the
rapidly advancing science and business of mRNA medicines. The
conference provides participants with a platform for networking
with experts, giving them an opportunity to learn more about
developments in mRNA technology and to see scientific presentations
by some of the most esteemed experts in the field. The event brings
together over 650 attendees from leading pharma and biotech
companies as well as academic institutions.
About PCI
Biotech PCI
Biotech is a biopharmaceutical late-stage clinical development
company focusing on development and commercialisation of novel
therapies for the treatment of cancer through its innovative
photochemical internalisation (PCI) technology platform. PCI is
applied to three distinct anticancer paradigms:
fimaChem (enhancement of
chemotherapeutics for localised treatment of cancer),
fimaVacc (T-cell induction
technology for therapeutic vaccination), and
fimaNAc (nucleic acid
therapeutics delivery).
Photochemical internalisation induces triggered
endosomal release that is used to unlock the true potential of a
wide array of therapeutic modalities. The company’s lead programme
fimaChem consists of
a pivotal study in bile duct cancer, an orphan indication with
a high unmet need and without approved products.
fimaVacc applies a unique mode of
action to enhance the essential cytotoxic effect of therapeutic
cancer vaccines, which works in synergy with several other
state-of-the-art vaccination technologies.
fimaNAc utilises the endosomal
release to provide intracellular delivery of nucleic acids, such as
mRNA and RNAi therapeutics, thereby addressing one of the major
bottlenecks facing this emerging and promising field.
For further information, please visit:
www.pcibiotech.com
Forward-looking
statements This
announcement may contain forward-looking statements, which as such
are not historical facts, but are based upon various assumptions,
many of which are based, in turn, upon further assumptions. These
assumptions are inherently subject to significant known and unknown
risks, uncertainties and other important factors. Such risks,
uncertainties, contingencies and other important factors could
cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking
statements. PCI Biotech disclaims any obligation to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
- PCI Biotech Poster Int mRNA Health Conf Nov 2021
Pci Biotech Holding Asa (LSE:0JGL)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Pci Biotech Holding Asa (LSE:0JGL)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
